Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-0.18%+4.35%+4.23%+30.02% 47.86B
-0.67%-0.30%+43.74%+32.42% 44.46B
-1.12%+4.70%+10.75%+91.43% 41.85B
-1.00%-2.29%+333.05%+548.92% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-1.48%+0.17%+24.46%+152.34% 17.59B
-6.73%-9.65% - - 15.6B
-3.55%+1.95%+21.97%+39.13% 15.69B
-1.41%+8.78%-9.53% - 13.93B
Average -1.09%+2.66%+54.85%+134.32% 29.82B
Weighted average by Cap. -1.27%+1.88%+68.49%+142.66%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!